» Articles » PMID: 34091453

Post Hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides

Overview
Journal Dermatology
Publisher Karger
Specialty Dermatology
Date 2021 Jun 6
PMID 34091453
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma. Patients can be treated using chlormethine gel, a skin-directed therapy developed and approved for MF. In the randomized, controlled 201 trial, chlormethine gel was found to be noninferior to equal-strength chlormethine ointment. However, there remains a need to gain more insight into outcome measures after treatment.

Objective: The aim of this study was to further investigate the potential of chlormethine gel treatment through a novel post hoc analysis of the 201 trial data (NCT00168064).

Methods: Patients were randomized to chlormethine gel or ointment; response assessments included Composite Assessment of Index Lesion Severity (CAILS) and total body surface area (BSA). In this post hoc analysis, additional subgroup response analyses were performed for stage IA/IB-IIA MF. Very good partial response (75 to <100% improvement) was included as an additional response category. Time to response and overall response trends were determined. Finally, multivariate time-to-event analyses were performed to determine whether associations were observed between treatment frequency, response, and adverse events.

Results: Response rates were significantly higher for patients with stage IA MF for CAILS (intent-to-treat [p = 0.0014] and efficacy-evaluable [EE; p = 0.0036] populations) and BSA (EE population [p = 0.0488]) treated with gel versus ointment. Time to first CAILS response and response trends were better for all-stage gel-treated patients overall. No association was seen between treatment frequency and response or occurrence of adverse events at the following visit. An association was observed between the occurrence of contact dermatitis and improved clinical response at the next visit (p = 0.0001).

Conclusion: This post hoc analysis shows that treatment with chlormethine gel may result in higher and faster response rates compared with chlormethine ointment, which confirms and expands results reported in the original analysis. The incidence of contact dermatitis may potentially be a prognostic indicator for clinical response; this needs to be confirmed in a larger population.

Citing Articles

Chlormethine Gel for Treatment of Patients with Mycosis Fungoides: Best Practices and Guidance to Clinicians.

Geskin L, Querfeld C, Hodak E, Nikbakht N, Papadavid E, Ardigo M Dermatol Ther (Heidelb). 2024; 15(1):61-73.

PMID: 39602063 PMC: 11785887. DOI: 10.1007/s13555-024-01305-x.


Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial.

Assaf C, Querfeld C, Scandurra M, Turini M, Scarisbrick J Acta Derm Venereol. 2023; 103:adv00862.

PMID: 36748332 PMC: 9923407. DOI: 10.2340/actadv.v103.4881.


Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations.

Crimp C, Gangal A, Tarabadkar E, Shinohara M Cancer Manag Res. 2022; 14:3271-3279.

PMID: 36444357 PMC: 9700459. DOI: 10.2147/CMAR.S351420.


Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings.

Wehkamp U, Ardigo M, Papadavid E, Querfeld C, Nikbakht N Adv Ther. 2022; 39(9):3979-4002.

PMID: 35852707 PMC: 9294809. DOI: 10.1007/s12325-022-02219-w.


Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.

Querfeld C, Scarisbrick J, Assaf C, Kim Y, Guitart J, Quaglino P Am J Clin Dermatol. 2022; 23(4):561-570.

PMID: 35536441 PMC: 9334402. DOI: 10.1007/s40257-022-00687-y.


References
1.
Kim Y, Martinez G, Varghese A, Hoppe R . Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003; 139(2):165-73. DOI: 10.1001/archderm.139.2.165. View

2.
Duffy R, Jennings T, Sahu J . Mechlorethamine Gel Usage in Patients with Mycosis Fungoides in a Lymphoma Clinic. Indian J Dermatol. 2020; 65(3):237-239. PMC: 7292456. DOI: 10.4103/ijd.IJD_433_18. View

3.
Bobrowicz M, Fassnacht C, Ignatova D, Chang Y, Dimitriou F, Guenova E . Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020; 181(10):733-745. DOI: 10.1159/000509281. View

4.
Denis D, Beneton N, Laribi K, Maillard H . Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res. 2019; 11:2241-2251. PMC: 6433101. DOI: 10.2147/CMAR.S138661. View

5.
Geskin L, Kim E, Angello J, Kim Y . Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study. Clin Lymphoma Myeloma Leuk. 2020; 21(2):119-124.e4. DOI: 10.1016/j.clml.2020.11.022. View